Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study

Author:

Turc Guillaume1234,Calvet David1234,Guérin Patrice56,Sroussi Marjorie27,Chatellier Gilles289,Mas Jean‐Louis1234,

Affiliation:

1. Department of Neurology Hôpital Sainte‐Anne Paris France

2. Université Paris Descartes Sorbonne Paris Cité Paris France

3. NSERM U894 Paris France

4. DHU Neurovasc Paris France

5. Department of Cardiology INSERM UMR 915 Institut du Thorax Nantes France

6. Institut du Thorax Centre Hospitalier Universitaire de Nantes Nantes France

7. Department of Cardiology Cochin Hospital APHP Paris France

8. Epidemiology and Clinical Research Unit Georges Pompidou European Hospital APHP Paris France

9. INSERM CIC 1418 Paris France

Abstract

Background We conducted a systematic review and meta‐analysis of randomized controlled trials ( RCT s) comparing patent foramen ovale ( PFO ) closure, anticoagulation, and antiplatelet therapy to prevent stroke recurrence in patients with PFO ‐associated cryptogenic stroke. Methods and Results We searched Medline, Cochrane Library, and EMBASE through March 2018. The primary outcome was stroke recurrence. Pooled incidences, hazard ratios, and risk ratios ( RR s) were calculated in random‐effects meta‐analyses. PFO closure was associated with a lower risk of recurrent stroke compared with antithrombotic therapy (antiplatelet therapy or anticoagulation: 3560 patients from 6 RCT s; RR =0.36, 95% CI : 0.17–0.79; I 2 =59%). The effect of PFO closure on stroke recurrence was larger in patients with atrial septal aneurysm or large shunt ( RR =0.27, 95% CI , 0.11–0.70; I 2 =42%) compared with patients without these anatomical features ( RR =0.80, 95% CI , 0.43–1.47; I 2 =12%). Major complications occurred in 2.40% (95% CI , 1.03–4.25; I 2 =77%) of procedures. New‐onset atrial fibrillation was more frequent in patients randomized to PFO closure versus antithrombotic therapy ( RR =4.33, 95% CI , 2.37–7.89; I 2 =14%). One RCT compared PFO closure versus anticoagulation (353 patients; hazard ratio=0.14, 95% CI , 0.00–1.45) and 2 RCT s compared PFO closure versus antiplatelet therapy (1137 patients; hazard ratio=0.18, 95% CI , 0.05–0.63; I 2 =12%). Three RCT s compared anticoagulation versus antiplatelet therapy, with none showing a significant difference. Conclusions PFO closure is superior to antithrombotic therapy to prevent stroke recurrence after cryptogenic stroke. The annual absolute risk reduction of stroke was low, but it has to be tempered by a substantial time at risk (at least 5 years) in young and middle‐aged patients. PFO closure was associated with an increased risk of atrial fibrillation.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3